ISR Articles

51. Outsourcers' Opinions On CMO M&A Activity 9/15/2020

    In Q4, 2019, ISR asked 676 buyers of outsourced manufacturing services about their personal feelings regarding mergers and acquisitions in the contract manufacturing industry. One-third of respondents disagree-strongly disagree that M&A activity paves the way for better quality CMOs, while one-fifth of respondents agree-strongly agree. Nearly half neither agreed, nor disagreed that mergers and acquisitions impact the quality of contract manufacturers.

52. Reasons CDMOs Lose Bioprocessing Bids 9/15/2020

    In Q2 2020, ISR asked 100 respondents who outsource bioprocessing what is the main reason a CDMO may lose the bid for an outsourced bioprocessing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 32% of respondents’ votes.

53. Small Molecule Drug Product Outsourcing 8/17/2020

    In Q4 2019, ISR asked 176 outsourcers of small molecule drug product manufacturing about the proportion of work allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work (40%) is allocated to preferred providers, even though 43% of respondents work at companies that do not have preferred provider agreements.

54. The Importance Of Final Dosage Form For Clinical Trial Material 6/15/2020

    In Q4, 2019 ISR asked 100 outsourcers of clinical manufacturing how important it is for the clinical trial material, or IMP, to be in its final dosage form. 44% of respondents said it is very-extremely important for the IMP to be in the final dosage form. Another 47% said it is important. 

55. ISR's Contract Manufacturing Databook 4/1/2020

    It can be difficult to find industry specific, easy to interpret, trustworthy market data. Read the available eBook to discover free drug development and manufacturing facts, figures, and expert perspectives.

56. Comfort Level With Data Sharing 3/13/2020

    In Q4, 2019, ISR asked 676 outsourcers of manufacturing activities and services about their comfort level regarding data sharing between sponsors and service providers. The graph below shows how each of the data-sharing scenarios panned out, with sponsors being most comfortable with data sharing between their CMO and their own manufacturing department.

57. 3 Year Rolling Average – Small Molecule API Customer Loyalty 1/14/2020

    In Q4, 2019, ISR asked sponsors who outsource small molecule API to gain insight into customer loyalty. CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again. The data below show companies with ten or more responses from recent users for each of the past three years and an industry average derived from all CMOs included in the research; their loyalty component scores are aggregated, averaged and then weighted based on the number of customer interactions.

58. The Most Popular Oral Dosage Form 12/12/2019

    In Q2, 2019, ISR asked outsourcers of oral dose manufacturing several questions about the different oral dosage forms in their company’s portfolio. Below are the results for the most popular oral dosage form among respondents, the tablet.

59. Clinical Logistics Service Provider Use by Category 11/11/2019

    In Q3, 2019, ISR asked outsourcers of clinical logistics about the types of service providers they use and prefer for clinical logistics. The data show the majority of outsourcers use integrated clinical trial service providers (79%), specialty couriers (71%) and package delivery companies’ healthcare offering (63%).

60. Top Five Oral Dosage Forms By Portfolio Composition 9/12/2019

    The top five oral dosage forms account for more than half of products in oral dose portfolios and are: tablets, capsules, controlled release tablets, controlled release capsules, and immediate release tablets.